Generalized Anxiety Disorder (GAD) News and Research

RSS

Anxiety in poor mothers not a psychiatric problem but a reaction to severe environmental deficits

Poor mothers are more likely to be classified as having the mental illness known as generalized anxiety disorder (GAD) because they live in poverty - not because they are suffering from a psychiatric disorder, according to Rutgers researchers.

21 Jul 2012

Intelligence may have co-evolved with worry in humans

Worrying may have evolved along with intelligence as a beneficial trait, according to a recent study by scientists at SUNY Downstate Medical Center and other institutions.

16 Apr 2012

Teva, IVAX receive FDA approval for generic Lexapro to treat depression and GAD

The U.S. Food and Drug Administration today approved the first generic Lexapro (escitalopram tablets) to treat both depression and generalized anxiety disorder in adults.

27 Mar 2012

Exercise training can reduce worry symptoms among GAD patients

This study demonstrates that exercise training, including resistance exercise training, is a feasible, low-risk treatment that can potentially reduce worry symptoms among generalized anxiety disorder (GAD) patients and may be an effective adjuvant, short-term treatment or augmentation for GAD.

15 Mar 2012

Children with chronic sleep problems may develop mental health disorders later in life

Children who have chronic sleep problems may be much more likely to develop mental health disorders as adolescents and adults, according to Candice Alfano, associate professor in clinical psychology at the University of Houston (UH) and director of the new Sleep and Anxiety Center for Kids (SACK).

11 Jan 2012

Interpersonal relationships in individuals with generalized anxiety disorder: Study

Most people worry from time to time. A new research study, led by a Case Western Reserve University faculty member in psychology, also shows that worrying can be so intrusive and obsessive that it interferes in the person's life and endangers the health of social relationships.

27 Jul 2011

Mexican-born migrants may face high risk of developing depressive, anxiety disorders

People who migrate to the United States from Mexico have a significantly higher risk of developing depressive or anxiety disorders than family members of migrants who remain in Mexico, according to a report in the April issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

5 Apr 2011

USFDA grants Sun Pharma tentative marketing approval for generic Cymbalta

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules.

24 Nov 2010

Treatment options available for GAD

A little worry is normal, but people who constantly worry about daily concerns, even when times are good, may have generalized anxiety disorder.

22 Mar 2010

Chamomile extract therapy effective for generalized anxiety disorder

Feeling stressed? Try chamomile! This 'traditional' remedy has been around for years, but how much truth is there behind this old wives' tale?

10 Feb 2010

Pfizer's new pipeline shows growth and diversity in research and development

Pfizer Inc. today provided an update to its pipeline for the first time since the close of the acquisition of Wyeth in October, 2009. The new development pipeline, composed of assets from both legacy companies, includes 133 programs from phase 1 through registration, and shows growth and increased diversity in each of the areas where the company invests in research and development.

28 Jan 2010

FDA issues Pfizer a Complete Response letter for Lyrica GAD monotherapy treatment

Pfizer Inc. announced today that the Food and Drug Administration (FDA) issued a Complete Response letter regarding the company’s New Drug Application (NDA) for Lyrica® (pregabalin) capsules CV as a monotherapy treatment for generalized anxiety disorder (GAD). The FDA determined that the data contained in the NDA were insufficient to support approval.

24 Dec 2009

Survey provides comprehensive look at prevalence of common mental disorders

Only about half of American children and teenagers who have certain mental disorders receive professional services, according to a nationally representative survey funded in part by the National Institute of Mental Health (NIMH). The survey also provides a comprehensive look at the prevalence of common mental disorders.

14 Dec 2009

Eli Lilly's Cymbalta receives FDA approval

The U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, announced Eli Lilly and Company (NYSE: LLY).

30 Nov 2009

New therapy for decreasing anxiety and improving psychological well-being in children

A group of investigators of the University of Bologna suggest a new way of approaching emotional disturbances in children by improving their psychological well-being. The study is published in the current issue of Psychotherapy and Psychosomatics.

27 Oct 2009

Seroquel XR supplemental NDA recommended for approval

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) conducted a review of the safety and efficacy of supplemental new drug applications (sNDA) for Seroquel XR (quetiapine fumarate) extended-release tablets proposed for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

9 Apr 2009

Cognitive behavior therapy helps seniors with generalized anxiety disorder

Older adults with generalized anxiety disorder who received cognitive behavior therapy had greater improvement on measures of worry, depression and mental health than patients who received usual care, according to a study in the April 8 issue of JAMA, the Journal of the American Medical Association.

8 Apr 2009